Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance ...
(PR-inside.com) MALMÖ, SE / ACCESS Newswire / August 17, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type A meeting for September 9, 2026 to disc…
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


